Riders · Department of State Health Services · Article II: Health and Human Services

HIV Injectable Treatment

Rider 31 in the 2026-27 Act, page II-32

2028-29 request. Department of State Health Services has asked to delete this rider. What it asked for. A request, not law.

Through the session

  1. 2024-25 Act Not in this version
  2. Introduced (Senate) Not in this version
  3. Introduced (House) Not in this version
  4. Senate substitute Not in this version
  5. House substitute Not in this version
  6. House passed Not in this version
  7. Conference New rider 31
  8. 2026-27 Act Unchanged rider 31

Pick any two steps to compare their wording.

What changed in the text

Conference → 2026-27 Act: the same text in both versions.

HIV Injectable Treatment. Out of funds appropriated above in Strategy A.2.2, HIV/STD Prevention, the Department of State Health Services (DSHS) shall allocate $300,000 in fiscal year 2026 and $300,000 in fiscal year 2027 from the General Revenue Fund to pilot a program to provide HIV injectable treatment for up to 210 clients eligible for the Texas AIDS Drug Assistance Program (ADAP). DSHS shall prioritize clients in the following order based on available funding: (a) Clients eligible for the Texas Insurance Assistance Program-PLUS (TIAP-PLUS) and are waiting for the open enrollment period. If funds are not exhausted in item (a), DSHS shall prioritize clients in the following order based on available funding: (b) Clients who are eligible for TIAP-PLUS but do not enroll to maintain continuity of care with their local provider; and (c) Other clients eligible for ADAP. Contingent on DSHS collecting HIV rebate revenue in excess of $29,500,000 in fiscal year 2026 or $65,400,000 in fiscal year 2027, the appropriation in Strategy A.2.2, HIV/STD Prevention, shall be reduced by the amount that the HIV rebate revenue exceeds the amounts listed above up to $300,000 in fiscal year 2026 and $300,000 in fiscal year 2027.

Removed words are struck through; added words are underlined. Sources: Conference · 2026-27 Act.

Every version: numbers, statuses and source pages
VersionRider Against the version beforeAgainst the current budget Source
2024-25 ActGeneral Appropriations Act, 2024-25 Biennium Not in this version
Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) Not in this version
Introduced (House)House Bill 1 as introduced (LBB recommended, House) Not in this version
Senate substituteCommittee Substitute for Senate Bill 1 Not in this version
House substituteHouse Committee Substitute for Senate Bill 1 Not in this version
House passedSenate Bill 1 as passed the second house Not in this version
ConferenceConference Committee Report for Senate Bill 1 31 New New Page II-31
2026-27 ActGeneral Appropriations Act, 2026-27 Biennium 31 Unchanged New Page II-32
Full text of each wording

Conference, 2026-27 Act

Source, page II-32

HIV Injectable Treatment. Out of funds appropriated above in Strategy A.2.2, HIV/STD Prevention, the Department of State Health Services (DSHS) shall allocate $300,000 in fiscal year 2026 and $300,000 in fiscal year 2027 from the General Revenue Fund to pilot a program to provide HIV injectable treatment for up to 210 clients eligible for the Texas AIDS Drug Assistance Program (ADAP). DSHS shall prioritize clients in the following order based on available funding:

(a) Clients eligible for the Texas Insurance Assistance Program-PLUS (TIAP-PLUS) and are waiting for the open enrollment period. If funds are not exhausted in item (a), DSHS shall prioritize clients in the following order based on available funding:

(b) Clients who are eligible for TIAP-PLUS but do not enroll to maintain continuity of care with their local provider; and

(c) Other clients eligible for ADAP. Contingent on DSHS collecting HIV rebate revenue in excess of $29,500,000 in fiscal year 2026 or $65,400,000 in fiscal year 2027, the appropriation in Strategy A.2.2, HIV/STD Prevention, shall be reduced by the amount that the HIV rebate revenue exceeds the amounts listed above up to $300,000 in fiscal year 2026 and $300,000 in fiscal year 2027.